Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no

Keyphrases

• Glucagon-like 100%
• Dipeptidyl peptidase-4 (DPP-4) 100%
• A1 Receptor 87%
• Receptor Agonist 75%
• Blood Pressure Control 12%
• Systolic Blood Pressure 12%
• Delayed Diagnosis 12%
• Patient's Will 12%
• Hemoglobin A1c (HbA1c) 12%
• Type 2 Diabetic Patients 12%
• Metformin 12%
• Combination Treatment 12%
• Nausea 12%
• Lose Weight 12%
• Gastric Emptying 12%
• Glucagon Secretion 12%
• Insulin Secretion 12%
• Receptor Signaling 12%
• Vomiting 12%
• Minimal Risk 12%
• Antidiabetic Treatment 12%
• Basal Insulin 12%
• Hypoglycemia Risk 12%
• Incretin-based Therapy 12%
• Secretion Inhibition 12%
• Lifestyle Treatment 12%
• Oral Antidiabetic Agents 12%
• Antidiabetic Properties 12%

Medicine and Dentistry

• Glucagon-Like Peptide-1 Agonist 100%
• Dipeptidyl Peptidase-4 Inhibitor 100%
• Antidiabetic Agent 28%
• Systolic Blood Pressure 14%
• Side Effect 14%
• Oral Antidiabetic Agent 14%
• Hemoglobin A1c 14%
• Hypoglycemia 14%
• Glycon 14%
• Diabetes Mellitus 14%
• Incretin 14%
• Insulin Release 14%
• Glucagon Release 14%
• Stomach Emptying 14%
• Pressure Control 14%
• Nausea and Vomiting 14%
• Glucagon Like Peptide 1 Receptor 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucagon Like Peptide 1 Receptor Agonist 100%
• Dipeptidyl Peptidase IV Inhibitor 100%
• Antidiabetic Agent 28%
• Side Effect 14%
• Hypoglycemia 14%
• Hemoglobin A1c 14%
• Oral Antidiabetic Agent 14%
• Metformin 14%
• Nausea and Vomiting 14%
• Diabetes Mellitus 14%
• Glucagon 14%
• Incretin 14%
• Glucagon-Like Peptide 1 Receptor 14%